Lundbeck sues competitor for infringing on patent rights

Lundbeck and Otsuka are alleging that pharmaceutical firm Viatris’s proposed drug is in violation of eight patents.

Photo: Jens Dresling

Pharmaceutical firm Lundbeck has filed a lawsuit in the US against Viatris for violating the patent protection of schizophrenia drug Abilify Maintena, Bloomberg News reports.

A total of two lawsuits have been filed alongside Otsuka, which is behind the drug and has exclusively licensed it to Lundbeck.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs